Top analyst sizes up windfall billions for Pfizer, Regeneron and Eli Lilly in a big week for the Covid-19 R&D race
Pfizer CEO Albert Bourla’s $5.6 million personal windfall from stock sales on the same day the pharma giant exhilarated much of the world with 90%-plus protection rates for its Covid-19 vaccine underscores that there’s a significant amount of money riding on who gets to home base with the first approvals for pandemic remedies.
SVB Leerink’s Geoffrey Porges has been running the numbers in this field, and he took some time to assess Eli Lilly’s win this week over Regeneron in the antibody race. He didn’t expect Lilly to come out ahead, if at all, so he’s ratcheting down the sales estimates he expects for Regeneron by a bit, with $1.3 billion in revenue projected next year, followed by steadily dwindling revenue — $646 million in 2023 and $352 million in 2025.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free.